



Xencor to Present at Upcoming Investor Conferences

August 5, 2020

MONROVIA, Calif.--(BUSINESS WIRE)--Aug. 5, 2020-- Xencor, Inc. (NASDAQ:XCOR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate in three upcoming conferences:

- **BTIG Virtual Biotechnology Conference 2020**
Date: Monday, August 10, 2020
Presentation Time: 12:00 p.m. ET / 9:00 a.m. PT
- **2020 Webbush PacGrow Healthcare Virtual Conference**
Date: Wednesday, August 12, 2020
Presentation Time: 2:20 p.m. ET / 11:20 a.m. PT
- **Canaccord Genuity 40th Annual Growth Conference**
Date: Thursday, August 13, 2020
Panel Time: 1:00 p.m. ET / 10:00 a.m. PT

A live webcast of the presentations at the BTIG and Webbush conferences will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Replays will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 17 candidates engineered with Xencor's XmAb[®] technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200805005977/en/): <https://www.businesswire.com/news/home/20200805005977/en/>

Charles Liles
626-737-8118
cliles@xencor.com

Media Contact
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com

Source: Xencor, Inc.